Iran eyes producing 100 million doses of COVPars Vaccine

Tehran (IP)- Deputy head of the Razi Vaccine and Serum Research Institute, announced the production of the 100 million doses of the vaccine developed by the institute (COVPars).

Iran PressIran news: Razi COVPars Vaccine is the second Iranian-made coronavirus vaccine to enter the clinical trial phase.

The deputy head of the Razi Vaccine and Serum Research Institute, Mohammad-Hassan Fallah Mehrabadi, announced the production capacity of 100 million doses of Razi COVPars Vaccine has been provided by the end of next year in Iran (March 20, 2023) and added that the vaccine has been distributed and administered this week.

Mehrabadi said: "By the end of the current year (March 20, 2022), the institute can produce 30 million doses of COVPars."

Razi Vaccine and Serum Research Institute, with one hundred years of experience in vaccine production, has entered into COVID vaccine manufacturing since 2019.

Razi COVPars vaccine, the first recombinant Spike protein COVID vaccine, is made according to World Health Organization (WHO) guidelines.


Read more:

Iran's Razi-COV Pars vaccine entered third phase of clinical trial

Volunteers to receive 2nd dose of 'Cov Pars' vaccine in days